Indivior Pharmaceuticals, Inc. (INDV) Current Reports & Earnings Releases
Upcoming
- 2026-10-29 Earnings Release Estimated
| Filed | Form | Items | Filing |
|---|---|---|---|
| 2026-08-03 | 8-K | Material Agreement, Reg FD Disclosure, Financial Statements & Exhibits | SEC |
| 2026-08-03 | 8-K | Results of Operations, Reg FD Disclosure, Financial Statements & Exhibits | SEC |
| 2026-08-03 | 8-K | Reg FD Disclosure, Financial Statements & Exhibits | SEC |
| 2026-05-15 | 8-K | Officer / Director Changes, Shareholder Vote Results | SEC |
| 2026-05-04 | 8-K | Reg FD Disclosure, Other Events, Financial Statements & Exhibits | SEC |
| 2026-04-30 | 8-K | Results of Operations, Reg FD Disclosure, Financial Statements & Exhibits | SEC |
| 2026-03-17 | 8-K | Material Agreement, Termination of Agreement, Direct Financial Obligation, Unregistered Sales, Financial Statements & Exhibits | SEC |
| 2026-03-13 | 8-K | Other Events, Financial Statements & Exhibits | SEC |
| 2026-03-12 | 8-K | Other Events, Financial Statements & Exhibits | SEC |
| 2026-02-26 | 8-K | Results of Operations, Reg FD Disclosure, Financial Statements & Exhibits | SEC |
| 2026-01-26 | 8-K | Material Agreement, Direct Financial Obligation, Unregistered Sales, Item 3.03, Change in Control, Officer / Director Changes, Charter Amendments, Item 5.05, Reg FD Disclosure, Other Events, Financial Statements & Exhibits | SEC |
| 2026-01-08 | 8-K | Reg FD Disclosure, Financial Statements & Exhibits | SEC |
| 2025-12-22 | 8-K | Reg FD Disclosure, Financial Statements & Exhibits | SEC |
| 2025-12-18 | 8-K | Officer / Director Changes | SEC |
| 2025-12-15 | 8-K | Charter Amendments, Shareholder Vote Results, Financial Statements & Exhibits | SEC |
| 2025-11-20 | 8-K | Termination of Agreement, Reg FD Disclosure, Financial Statements & Exhibits | SEC |
| 2025-11-14 | 8-K | Reg FD Disclosure, Financial Statements & Exhibits | SEC |
| 2025-10-30 | 8-K | Results of Operations, Reg FD Disclosure, Financial Statements & Exhibits | SEC |
| 2025-10-01 | 8-K | Reg FD Disclosure, Financial Statements & Exhibits | SEC |
| 2025-08-26 | 8-K | Item 2.05 | SEC |
| 2025-08-22 | 8-K | Officer / Director Changes, Financial Statements & Exhibits | SEC |
| 2025-07-31 | 8-K | Results of Operations, Reg FD Disclosure, Financial Statements & Exhibits | SEC |
| 2025-06-30 | 8-K | Reg FD Disclosure, Financial Statements & Exhibits | SEC |
| 2025-06-24 | 8-K | Officer / Director Changes, Other Events, Financial Statements & Exhibits | SEC |
| 2025-06-02 | 8-K | Reg FD Disclosure, Financial Statements & Exhibits | SEC |
| 2025-06-02 | 8-K | Other Events, Financial Statements & Exhibits | SEC |
| 2025-05-08 | 8-K | Officer / Director Changes, Charter Amendments, Shareholder Vote Results, Reg FD Disclosure, Financial Statements & Exhibits | SEC |
| 2025-04-24 | 8-K | Results of Operations, Financial Statements & Exhibits | SEC |
| 2025-03-27 | 8-K | Reg FD Disclosure, Financial Statements & Exhibits | SEC |
| 2025-03-04 | 8-K | Material Agreement, Officer / Director Changes, Financial Statements & Exhibits | SEC |
| 2025-03-03 | 6-K | TOTAL VOTING RIGHTS | SEC |
| 2025-02-28 | 6-K | HOLDING(S) IN COMPANY | SEC |
| 2025-02-28 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2025-02-28 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2025-02-27 | 6-K | JOSEPH CIAFFONI APPOINTED CHIEF EXECUTIVE OFFICER | SEC |
| 2025-02-27 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2025-02-27 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2025-02-25 | 6-K | HOLDING(S) IN COMPANY | SEC |
| 2025-02-24 | 6-K | FDA APPROVAL OF SUBLOCADE LABEL CHANGES | SEC |
| 2025-02-20 | 6-K | — | SEC |
| 2025-02-12 | 6-K | DELAYED FDA APPROVAL OF SUBLOCADE LABEL CHANGES | SEC |
| 2025-02-04 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2025-02-04 | 6-K | COMPLETION OF SHARE REPURCHASE PROGRAM | SEC |
| 2025-02-04 | 6-K | NOTICE OF RESULTS | SEC |
| 2025-02-03 | 6-K | APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR | SEC |
| 2025-02-03 | 6-K | TOTAL VOTING RIGHTS | SEC |
| 2025-01-28 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2025-01-28 | 6-K | HOLDING(S) IN COMPANY | SEC |
| 2025-01-28 | 6-K | DR. DAVID WHEADON APPOINTED CHAIR OF THE BOARD | SEC |
| 2025-01-27 | 6-K | HOLDING(S) IN COMPANY | SEC |
| 2025-01-21 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2025-01-14 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2025-01-10 | 6-K | INDIVIOR PROVIDES HISTORICAL FINANCIALS IN US GAAP | SEC |
| 2025-01-07 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2025-01-07 | 6-K | HOLDING(S) IN COMPANY | SEC |
| 2025-01-02 | 6-K | TOTAL VOTING RIGHTS | SEC |
| 2024-12-31 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2024-12-31 | 6-K | HOLDING(S) IN COMPANY | SEC |
| 2024-12-26 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2024-12-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
Sourced from SEC EDGAR 8-K/6-K filings. 8-K is the current-report form for US domestic issuers (Item 2.02 = earnings release); 6-K is the equivalent for foreign private issuers, including ADRs. Originals live on sec.gov.